Alimentary Pharmacology & Therapeutics

Review article: hepatitis B and liver transplantation
pp. 1031-1041(11)
Author: MUTIMER, D.

Review article: predicting response in hepatitis C virus therapy
pp. 1043-1054(12)
Authors: MIHM, U.; HERRMANN, E.; SARRAZIN, C.; ZEUZEM, S.

Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options
pp. 1055-1065(11)
Author: GIANNINI, E. G.

Review article: intestinal serotonin signalling in irritable bowel syndrome
pp. 1067-1076(10)
Authors: MAWE, G. M.; COATES, M. D.; MOSES, P. L.

Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori?
pp. 1077-1086(10)
Authors: GOTTELAND, M.; BRUNSER, O.; CRUCHET, S.

Systematic review: the management of pouchitis
pp. 1087-1096(10)
Authors: PARDI, D. S.; SANDBORN, W. J.

Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease
pp. 1097-1104(8)
Authors: CANAVAN, C.; ABRAMS, K. R.; MAYBERRY, J.

Meta-analysis: the dialysis mode and immunological response to hepatitis B virus vaccine in dialysis population
pp. 1105-1112(8)
Authors: FABRIZI, F.; DIXIT, V.; BUNNAPRADIST, S.; MARTIN, P.

Personal view: a potential novel treatment for fatigue complicating chronic liver disease – how should its efficacy be evaluated?
pp. 1113-1116(4)
Author: JONES, E. A.

Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin
pp. 1117-1125(9)
Authors: PRANTERA, C.; LOCHS, H.; CAMPIERI, M.; SCRIBANO, M. L.; STURNIOLO, G. C.; CASTIGLIONE, F.; COTTONE, M.

Maintenance infliximab does not result in increased abscess development in fistulizing Crohn's disease: results from the ACCENT II study
pp. 1127-1136(10)
Authors: SANDS, B. E.; BLANK, M. A.; DIAMOND, R. H.; BARRETT, J. P.; DEVENTER, S. J.

Pharmacogenetics of thiopurine therapy in paediatric IBD patients
pp. 1137-1141(5)
Authors: RIDDER, L.; DIEREN, J. M.; DEVENTER, H. J. H.; STOKKERS, P. C. F.; WOUDE, J. C. J.; VUUREN, A. J.; BENNINGA, M. A.; ESCHER, J. C.; HOMMES, D. W.

Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study
pp. 1143-1151(9)
Authors: CAPANNI, M.; CALELLA, F.; BIAGINI, M. R.; GENISE, S.; RAIMONDI, L.; BEDOGNI, G.; SVEGLIATI-BARONI, G.; SOFI, F.; MILANI, S.; ABBATE, R.; SURRENTI, C.; CASINI, A.

Effect of anti-viral therapy for occult hepatitis C virus infection
pp. 1153-1159(7)
Authors: PARDO, M.; LÓPEZ-ALCOROCHO, J. M.; CASTILLO, I.; RODRÍGUEZ-IÑIGO, E.; PEREZ-MOTA, A.; CARREÑO, V.

Assessing patients' understanding of hepatitis C virus infection and its impact on their lifestyle
pp. 1161-1170(10)
Authors: FABRIS, P.; TOSITTI, G.; GIORDANI, M. T.; BALDO, V.; GRASSO, A.; PIGNATTARI, E.; CANTON, S.; ROSSATO, S.; FLOREANI, A.

48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection
pp. 1171-1178(8)
Authors: HUI, C.-K.; LAI, L. S. W.; LAM, P.; ZHANG, H.-Y.; FUNG, T.-T.; LAI, S.-T.; WONG, W.-M.; LO, C.-M.; FAN, S.-T.; LEUNG, N.; LAU, G. K. K.

Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three-way crossover study
pp. 1179-1187(9)
Authors: THOMSON, A. B. R.; COHEN, P.; FICHEUX, H.; FIORENTINI, P.; DOMAGALA, F.; HOMERIN, M.; TACCOEN, A.

Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole
pp. 1189-1196(8)
Authors: GOLDSTEIN, J. L.; MINER, P. B.; SCHLESINGER, P. K.; LIU, S.; SILBERG, D. G.

Oesophagitis is common in patients with achalasia after pneumatic dilatation
pp. 1197-1203(7)
Authors: LEEUWENBURGH, I.; DEKKEN, H.; SCHOLTEN, P.; HANSEN, B. E.; HARINGSMA, J.; SIERSEMA, P. D.; KUIPERS, E. J.

Pancreatic cancer in England and Wales 1975–2000: patterns and trends in incidence, survival and mortality
pp. 1205-1214(10)
Authors: WOOD, H. E.; GUPTA, S.; KANG, J. Y.; QUINN, M. J.; MAXWELL, J. D.; MUDAN, S.; MAJEED, A.

Reinfection after successful eradication of Helicobacter pylori: a 2-year prospective study in Alaska Natives
pp. 1215-1223(9)
Authors: McMAHON, B. J.; BRUCE, M. G.; HENNESSY, T. W.; BRUDEN, D. L.; SACCO, F.; PETERS, H.; HURLBURT, D. A.; MORRIS, J. M.; REASONOVER, A. L.; DAILIDE, G.; BERG, D. E.; PARKINSON, A. J.

Effects of low-dose aspirin on gastric erosions, cyclooxygenase expression and mucosal prostaglandin-E₂ do not depend on Helicobacter pylori infection
pp. 1225-1233(9)
Authors: VENERITO, M.; TREIBER, G.; WEX, T.; KUESTER, D.; ROESSNER, A.; DI MARIO, F.; MALFERTHEINER, P.

Bovine lactoferrin for Helicobacter pylori eradication: an open, randomized, multicentre study
pp. 1235-1240(6)
Authors: DI MARIO, F.; ARAGONA, G.; DAL BÓ, N.; CAVALLARO, L.; MARCON, V.; OLIVIERI, P.; BENEDETTI, E.; ORZÈS, N.; MARIN, R.; TAFNER, G.; CHILOVI, F.; DE BASTIANI, R.; FEDRIZZI, F.; FRANCESCHI, M.; SALVAT, M. H.; MONICA, F.; PIAZZI, L.; VALIANTE, F.; VECCHIATI, U.; CAVESTRO, G. M.; COMPARATO, G.; IORI, V.; MAINO, M.; LEANDRO, G.; PILOTTO, A.; RUGGE, M.; FRANZÈ, A.

Prokinetic effect of gut-oriented hypnosis on gastric emptying
pp. 1241-1249(9)
Authors: CHIARIONI, G.; VANTINI, I.; DE IORIO, F.; BENINI, L.

Effect of intravenous infusion of glyceryl trinitrate on gastric and small intestinal motor function in healthy humans
pp. 1251-1257(7)
Authors: MADSEN, J. L.; FUGLSANG, S.; GRAFF, J.

Polyethylene glycol 4000 vs. lactulose for the treatment of neurogenic constipation in myelomeningocele children: a randomized-controlled clinical trial
pp. 1259-1265(7)
Authors: RENDELI, C.; AUSILI, E.; TABACCO, F.; FOCARELLI, B.; PANTANELLA, A.; DI ROCCO, C.; GENOVESE, O.; FUNDARÒ, C.

The usefulness of transabdominal ultrasound for the diagnosis of lower gastrointestinal bleeding
pp. 1267-1272(6)
Authors: YAMAGUCHI, T.; MANABE, N.; HATA, J.; TANAKA, S.; HARUMA, K.; CHAYAMA, K.

Treatment of anaemia in inflammatory bowel disease
pp. 1273-1274(2)
Authors: Koutroubakis, I. E.; Karmiris, K.; Kouroumalis, E. A.

Treatment of anaemia in inflammatory bowel disease: authors' reply
pp. 1274-1275(2)
Authors: Silva, A.; Rampton, D. S.

Antibiotic prophylaxis for percutaneous endoscopic gastrostomy insertion in patients with non-malignant disease
pp. 1276-1277(2)
Authors: Robins, G.; Hull, M.

Antibiotic prophylaxis for percutaneous endoscopic gastrostomy insertion in patients with non-malignant disease: authors' reply
pp. 1277-1277(1)
Authors: Fisher, N. C.; Saadeddin, A.; Freshwater, D. A.; Jones, B. J. M.

Impracticalities of thiopurine S-methyltransferase determination in daily inflammatory bowel disease practice
pp. 1278-1279(2)
Authors: Boer, N. K. H.; Mulder, C. J. J.; Bodegraven, A. A.

Impracticalities of thiopurine-S-methyltransferase determination in daily inflammatory bowel disease practice: authors' reply
pp. 1279-1280(2)
Authors: Winter, J.; Mills, P. R.

Proton pump inhibitor failure in gastro-oesophageal reflux disease – what about eosinophilic oesophagitis?
pp. 1281-1281(1)
Authors: Sgouros, S. N.; Mantides, A.

Proton pump inhibitor failure in gastro-oesophagel reflux disease – what about eosinophilic oesophagitis? Authors' reply
pp. 1282-1283(2)
Authors: Fass, R.; Shapiro, M.

Levofloxacin-based rescue regimens after Helicobacter pylori treatment failure: how strong is the evidence?
pp. 1283-1285(3)
Authors: Yuan, Y.; Thabane, L.; Hunt, R. H.

Levofloxacin-based rescue regimens after Helicobacter pylori treatment failure: how strong is the evidence? Author's reply
pp. 1285-1286(2)
Author: Gisbert, J. P.